Inari Medical, Inc. (NARI)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Inari Medical, Inc. (“Inari” or “the Company”) (NASDAQ: NARI). Investors who purchased Inari securities prior to March 10, 2021, and continue to hold to the present, are encouraged to obtain additional… read more

iLearningEngines, Inc. (AILE)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of iLearningEngines, Inc. (“iLearningEngines” or “the Company”) (NASDAQ: AILE). Investors who purchased iLearningEngines securities prior to April 22, 2024, and continue to hold to the present, are encouraged to obtain additional information… read more

Keros Therapeutics, Inc. (KROS)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. (“Keros” or “the Company”) (NASDAQ: KROS). Investors who purchased Keros securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Keros has violated… read more

Bolt Biotherapeutics, Inc. (BOLT)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Bolt Biotherapeutics, Inc. (“Bolt” or “the Company”) (NASDAQ: BOLT). Investors who purchased Bolt securities prior to February 5, 2021, and continue to hold to the present, are encouraged to obtain additional… read more

Paladin Energy Ltd (PALAF)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Paladin Energy Ltd (“Paladin” or “the Company”) (OTCMKTS: PALAF). Investors who purchased Paladin securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Paladin has violated… read more

XPEL, Inc. (XPEL)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of XPEL, Inc. (“XPEL” or “the Company”) (NASDAQ: XPEL). Investors who purchased XPEL securities prior to November 8, 2023, and continue to hold to the present, are encouraged to obtain additional information… read more

Vicor Corporation (VICR)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Vicor Corporation (“Vicor” or “the Company”) (NASDAQ: VICR). Investors who purchased Vicor securities prior to April 26, 2023, and continue to hold to the present, are encouraged to obtain additional information… read more

Methode Electronics, Inc. (MEI)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Methode Electronics, Inc. (“Methode Electronics” or “the Company”) (NYSE: MEI). Investors who purchased Methode Electronics securities prior to December 2, 2021, and continue to hold to the present, are encouraged to… read more

Malibu Boats, Inc. (MBUU)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Malibu Boats, Inc. (“Malibu Boats” or “the Company”) (NASDAQ: MBUU). Investors who purchased Malibu Boats securities prior to November 4, 2022, and continue to hold to the present, are encouraged to… read more

Lifecore Biomedical, Inc. (LFCR)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. (“Lifecore” or “the Company”) (NASDAQ: LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional… read more

Globe Life Inc. (GL)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Globe Life Inc. (“Globe Life” or “the Company”) (NYSE: GL). Investors who purchased Globe Life securities prior to May 8, 2019, and continue to hold to the present, are encouraged to… read more

Equinix, Inc. (EQIX)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Equinix, Inc. (“Equinix” or “the Company”) (NASDAQ: EQIX). Investors who purchased Equinix securities prior to May 3, 2019, and continue to hold to the present, are encouraged to obtain additional information… read more

EngageSmart, Inc. (ESMT)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of EngageSmart, Inc. (“EngageSmart” or “the Company”) (NYSE: ESMT). Investors who purchased EngageSmart securities prior to October 23, 2023, and continue to hold to the present, are encouraged to obtain additional information… read more

Domino’s Pizza, Inc. (DPZ)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Domino’s Pizza, Inc. (“Domino’s” or “the Company”) (NYSE: DPZ). Investors who purchased Domino’s securities prior to December 7, 2023, and continue to hold to the present, are encouraged to obtain additional… read more

Direct Digital Holdings Inc. (DRCT)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Direct Digital Holdings Inc. (“Direct Digital” or “the Company”) (NASDAQ: DRCT). Investors who purchased Direct Digital securities prior to April 17, 2023, and continue to hold to the present, are encouraged… read more

Dick’s Sporting Goods, Inc. (DKS)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dick’s Sporting Goods, Inc. (“Dick’s” or “the Company”) (NYSE: DKS). Investors who purchased Dick’s securities prior to May 25, 2022, and continue to hold to the present, are encouraged to obtain… read more

BioVie Inc. (BIVI)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioVie Inc. (“BioVie” or “the Company”) (NASDAQ: BIVI). Investors who purchased BioVie securities prior to December 7, 2022, and continue to hold to the present, are encouraged to obtain additional information… read more

Amylyx Pharmaceuticals, Inc. (AMLX)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. (“Amylyx” or “the Company”) (NASDAQ: AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional… read more

Akero Therapeutics, Inc. (AKRO)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. (“Akero” or “the Company”) (NASDAQ: AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional… read more

HelloFresh SE (HLFFF)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of HelloFresh SE (“HelloFresh” or “the Company”) (OTCMKTS: HLFFF). Investors who purchased HelloFresh securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether HelloFresh has violated federal… read more

BioAge Labs, Inc. (BIOA)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioAge Labs, Inc. (“BioAge Labs” or “the Company”) (NASDAQ: BIOA). Investors who purchased BioAge Labs securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether BioAge… read more

Five Below, Inc. (FIVE)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Five Below, Inc. (“Five Below” or “the Company”) (NASDAQ: FIVE). Investors who purchased Five Below securities prior to December 1, 2022, and continue to hold to the present, are encouraged to… read more

Silvaco Group, Inc. (SVCO)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Silvaco Group, Inc. (“Silvaco” or “the Company”) (NASDAQ: SVCO). Investors who purchased Silvaco securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Silvaco has violated… read more

Pactiv Evergreen Inc. (PTVE)

Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Pactiv Evergreen Inc. (“Pactiv Evergreen”) (NASDAQ: PTVE) and Novolex®. Investors who purchased Pactiv Evergreen and continue to hold to the present are encouraged to obtain additional information and assist the investigation. Investigation Details The investigation… read more

Coinbase Global, Inc. (COIN)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Coinbase Global, Inc. (“Coinbase” or “the Company”) (NASDAQ: COIN). Investors who purchased Coinbase securities prior to April 14, 2021, and continue to hold to the present, are encouraged to obtain additional… read more

HelloFresh SE (HLFFF)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of HelloFresh SE (“HelloFresh” or “the Company”) (OTCMKTS: HLFFF). Investors who purchased HelloFresh securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether HelloFresh has violated federal… read more

Franklin Resources, Inc. (BEN)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Franklin Resources, Inc. (“Franklin” or “the Company”) (NYSE: BEN). Investors who purchased Franklin securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Franklin has violated… read more

ICON Public Limited Company (ICLR)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ICON Public Limited Company (“ICON” or “the Company”) (NASDAQ: ICLR). Investors who purchased ICON securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether ICON has… read more

Orthofix Medical Inc. (OFIX)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Orthofix Medical Inc. (“Orthofix” or “the Company”) (NASDAQ: OFIX). Investors who purchased Orthofix securities prior to October 11, 2022, and continue to hold to the present, are encouraged to obtain additional… read more

Sprinklr, Inc. (CXM)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sprinklr, Inc. (“Sprinklr” or “the Company”) (NYSE: CXM). Investors who purchased Sprinklr securities prior to March 29, 2023, and continue to hold to the present, are encouraged to obtain additional information… read more